Skip to content
zameds

Diclofenac (Veltex Cr, Adco-diclofenac Sr, Veltex, Adco-diclofenac, Diclofenac Clicks, Voltaren Ophtha)

Diclofenac

Adcock ingram limited

Registration

Applicant
Adcock ingram limited
Registrations
8

Variants

ProductStrength and formRegistrationStatusScheduleLeaflets
Veltex 75 cr

EACH CAPSULE CONTAINS DICLOFENAC SODIUM 75 mg

7527032127/3.1/0321RegisteredNot determinedNone
Adco-diclofenac sr 100 MG

EACH CAPSULE CONTAINS DICLOFENAC SODIUM 100 mg

100 mg27040227/3.1/0402RegisteredNot determinedNone
Veltex ampoules

EACH 3 ml AMPOULE CONTAINS DICLOFENAC SODIUM 75,0 mg

Ampoules29039429/3.1/0394CancelledNot determinedNone
Adco-diclofenac 75

EACH 3 ml SOLUTION CONTAINS DICLOFENAC SODIUM 75,0 mg

75U0174U/3.1/174RegisteredNot determinedNone
Adco-diclofenac 25 MG

EACH TABLET CONTAINS DICLOFENAC SODIUM 25 mg

25 mgU0181U/3.1/181RegisteredNot determinedNone
Diclofenac 50 MG clicks

EACH TABLET CONTAINS DICLOFENAC SODIUM 50 mg

50 mgTabletsU0182U/3.1/182Approved 11 May 2021RegisteredNot determinedPIPIL
Voltaren ophtha

EACH 1 ml CNTAINS DICLOFENAC SODIUM 1 mg

Not listedW0204W/15.4/204RegisteredNot determinedNone
Veltex 100 cr

EACH CAPSULE CONTAINS DICLOFENAC SODIUM 100 mg

100W0329W/3.1/329RegisteredNot determinedNone

Regulatory status

This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.

Listings for this ingredient that could not be applied to this product

  • S3: Diclofenac

    • except when intended for application to the skin and containing 1 % m/m or less of diclofenac subject to a maximum pack size of 50 grams; (S0)
    • except when intended for application to the skin and containing more than 1 % m/m of diclofenac; (S1)
    • except when intended for the emergency treatment of acute gout attacks, subject to a maximum daily dose of 150 mg for a maximum treatment period of 3 days; (S2)
    • except when intended for human use only in the treatment of fever or mild to moderate pain of inflammatory origin, or for the treatment of post-traumatic conditions subject to a maximum daily dose of 75 mg for a maximum treatment period of 5 days. (S2)

    Consolidated Schedules 06 July 2026, lines 3415 to 3427

  • S2: Diclofenac

    • when intended for the emergency treatment of acute gout attacks, subject to a maximum daily dose of 150 mg for a maximum treatment period of 3 days; (S3)
    • when intended for human use only in the treatment of fever or mild to moderate pain of inflammatory origin, or for the treatment of post-traumatic conditions, subject to a maximum daily dose of 75 mg for a maximum treatment period of 5 days;
    • except when intended for application to the skin and containing 1 % m/m or less of diclofenac subject to a maximum pack size of 50 grams; (S0)
    • except when intended for application to the skin and containing more than 1 % m/m of diclofenac; (S1)
    • except when intended for veterinary use. (S3)

    Consolidated Schedules 06 July 2026, lines 1807 to 1821

  • S1: Diclofenac

    • when intended for application to the skin and containing more than 1 % m/m of diclofenac; (S3)
    • except when intended for application to the skin and containing 1 % m/m or less of diclofenac subject to a maximum pack size of 50 grams; (S0)
    • except when intended for the emergency treatment of acute gout attacks, subject to a maximum daily dose of 150 mg for a maximum treatment period of 3 days; (S2)
    • except when intended for human use only in the treatment of fever or mild to moderate pain of inflammatory origin, or for the treatment of post-traumatic conditions, subject to a maximum daily dose of 75 mg for a maximum treatment period of 5 day; (S2)
    • except when intended for veterinary use. (S3)

    Consolidated Schedules 06 July 2026, lines 365 to 379

This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.

C14H11Cl2NO2296.10 g/mol

2-[2-(2,6-Dichloroanilino)phenyl]acetic acid

Drag to rotate. Structure from PubChem CID 3033.

SAHPRA documents

Professional information (PI)For healthcare professionalsPatient information leaflet (PIL)For patients and carers

These documents are provided by SAHPRA for informational purposes. Always consult with a healthcare professional for medical advice.

Background

Loading...
Loading Wikipedia summary

Research articles

Loading...
Loading PubMed articles